Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 130 entries
View as:

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03137004 Org: User:
Start: 06/01/17 End: 10/10/18 Due: 10/10/19

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05882630 Org: User:
Start: 06/01/23 End: 06/01/26 Due: 06/01/27

Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life

Phase: N/A Priority: Normal
NCT ID: NCT06136962 Org: User:
Start: 12/01/23 End: 12/01/24 Due: 12/01/25

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05314101 Org: User:
Start: 04/01/22 End: 02/28/24 Due: 02/28/25

Almonertinib Plus Metronomic Oral Vinorelbine

Phase: N/A Priority: Normal
NCT ID: NCT05663177 Org: User:
Start: 12/20/22 End: 06/01/24 Due: 06/01/25

Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05266820 Org: User:
Start: 10/01/21 End: 12/01/23 Due: 12/01/24

Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06775756 Org: User:
Start: 04/01/25 End: 04/01/30 Due: 04/01/31

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06538935 Org: User:
Start: 01/31/25 End: 12/31/27 Due: 12/31/28

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06331845 Org: User:
Start: 05/01/24 End: 05/01/28 Due: 05/01/29

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06260553 Org: User:
Start: 02/07/24 End: 08/07/25 Due: 08/07/26

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Phase: N/A Priority: Normal
NCT ID: NCT03045770 Org: User:
Start: 02/10/17 End: 12/30/19 Due: 12/30/20

Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03244904 Org: User:
Start: 11/30/17 End: 07/31/18 Due: 07/31/19

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03708536 Org: User:
Start: 11/30/18 End: 11/30/22 Due: 11/30/23

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04174339 Org: User:
Start: 12/10/19 End: 05/02/21 Due: 05/02/22

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06149767 Org: User:
Start: 01/31/24 End: 03/31/28 Due: 03/31/29

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Phase: N/A Priority: Normal
NCT ID: NCT04785768 Org: User:
Start: 07/01/21 End: 07/01/24 Due: 07/01/25

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05628610 Org: User:
Start: 09/30/24 End: 09/30/27 Due: 09/30/28

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Phase: N/A Priority: Normal
NCT ID: NCT02865304 Org: User:
Start: 12/31/16 End: 12/31/18 Due: 12/31/19

Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04319471 Org: User:
Start: 06/01/20 End: 06/01/23 Due: 06/01/24

XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05927844 Org: User:
Start: 06/30/23 End: 06/30/25 Due: 06/30/26

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT06787183 Org: User:
Start: 03/01/25 End: 12/01/27 Due: 12/01/28

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase: N/A Priority: Normal
NCT ID: NCT05319639 Org: User:
Start: 02/16/23 End: 12/31/25 Due: 12/31/26

the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05131243 Org: User:
Start: 12/01/21 End: 05/01/23 Due: 05/01/24

Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT03566576 Org: User:
Start: 07/01/18 End: 10/01/18 Due: 10/01/19

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04354961 Org: User:
Start: 05/07/21 End: 06/30/25 Due: 06/30/26